About: Anakinra

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Anakinra Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor antagonist (IL-1Ra). The difference between anakinra and the native human IL-1Ra is that anakinra has an extra methionine residue at the amino terminus. It is manufactured by using the E. coli expression system. Anakinra is composed of 153 amino acid residues. FDA approved on November 14, 2001. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B4039-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B403A-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352 # Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loët X, Sibilia J; Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP); Club Rhumatismes et Inflammation (CRI): Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008 Mar;67(3):281-2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17947302 # FDA label (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	Healthy subjects = 4 - 6 hours; NOMID patients = 5.7 hours (range of 3.1 - 28.2 hours). (en)
http://linked.open...ugbank/indication	For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID). (en)
sameAs	Anakinra Anakinra
Title	Anakinra (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB00026/identifier/drugbank/DB00026 http://linked.opendata.cz/resource/drugbank/drug/DB00026/identifier/genbank/M55646 http://linked.opendata.cz/resource/drugbank/drug/DB00026/identifier/kegg-drug/D02934 http://linked.opendata.cz/resource/drugbank/drug/DB00026/identifier/pharmgkb/PA10799 http://linked.opendata.cz/resource/drugbank/drug/DB00026/identifier/uniprotkb/P18510 http://linked.opendata.cz/resource/drugbank/drug/DB00026/identifier/national-drug-code-directory/66658-234-28 http://linked.opendata.cz/resource/drugbank/drug/DB00026/identifier/wikipedia/Anakinra
http://linked.open...mechanismOfAction	Anakinra binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption. (en)
http://linked.open...drugbank/packager	Amgen Inc. Bausch and lomb pharmaceuticals inc
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/1341322 http://linked.opendata.cz/resource/drugbank/patent/2141953
http://linked.open.../drugbank/synonym	Interleukin-1 receptor antagonist protein precursor (en) ICIL-1RA (en) IL-1RN (en) IL-1ra (en) IL1 inhibitor (en) IRAP (en)
http://linked.open...drugbank/toxicity	Most common adverse reactions (incidence ≥ 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu like-symptoms, and abdominal pain when anakinra is used in RA patients. In NOMID patients, the most common AEs during the first 6 months of treatment (incidence >10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis. (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/92-00-00
http://linked.open...y/mesh/hasConcept	http://linked.opendata.cz/resource/mesh/concept/M0494869
foaf:page	http://www.drugs.com/cdi/anakinra.html http://www.rxlist.com/cgi/generic/anakinra.htm
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B403E-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B403D-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Anakinra
http://linked.open...ugbank/absorption	When a 70 mg subcutaneous bolus injection is given to healthy subjects, the absolute bioavailability is 95%. Accumulation does not occur following daily subcutaneous doses. Tmax, SubQ, 1-2 mg/kg, healthy subjects = 3-7 hours; Cmax, SubQ, 3 mg/kg once daily, NOMID patients = 3628 ng/mL. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	143090-92-0 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	Clearance is variable and increases with increasing creatinine clearance and body weight. However, gender and age were not significant factors. (en)
http://linked.open...gbank/containedIn	Kineret 100 mg/0.67 ml syr Kineret 1 Box = 7 Syringes, 4.69ml Box
http://linked.open...nk/Hydrophobicity	http://linked.opendata.cz/resource/drugbank/property/271B403B-363D-11E5-9242-09173F13E4C5
http://linked.open...Isoelectric-Point	http://linked.opendata.cz/resource/drugbank/property/271B403C-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.116 as of Feb 22 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of Feb 22 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software